Division of General, Oncological, Mini-invasive and Obesity Surgery, University of Study of Campania "Luigi Vanvitelli", via Luigi Pansini n° 5, 80131, Naples, Italy.
Department of Emergency Surgery, "A. Cardarelli" Hospital, Via A. Cardarelli 9, Naples, Italy.
Langenbecks Arch Surg. 2023 Apr 5;408(1):140. doi: 10.1007/s00423-023-02879-4.
Hemorrhoidal disease (HD) is a common condition, and several surgical techniques have been proposed to date without being able to achieve definitive consensus on their use and indications. Laser hemorrhoidoplasty (LHP) is a minimally invasive procedure for HD treatment determining the shrinkage of the hemorrhoidal piles by diode laser limiting the postoperative discomfort and pain. The aim of the current study was to evaluate the postoperative outcomes of HD patients undergoing LHP vs conventional Milligan-Morgan hemorrhoidectomy (MM).
Postoperative pain, wound care management, symptoms' resolution, patients' quality of life, and length of return to daily activity of grade III symptomatic HD patients undergoing LHP vs MM were retrospectively evaluated. The patients were followed-up for recurrence of prolapsed hemorrhoid or symptoms.
From January 2018 to December 2019, 93 patients received conventional Milligan Morgan as control group and 81 patients received laser hemorrhoidoplasty treatment using a 1470-nm diode laser. No significant intraoperative complications occurred in both groups. Laser hemorrhoidoplasty patients experienced lower postoperative pain score (p < 0.0001) and smoother wound management. After 25 ± 8 months follow-up, the recurrence of symptoms occurred in 8.1% after Milligan-Morgan and 21.6% after laser hemorrhoidoplasty (p < 0.05) with a similar Rorvik score (7.8 ± 2.6 in LHP group vs 7.6 ± 1.9 in MM group, p = 0.12).
LHP demonstrated high efficacy in selected HD patients guaranteeing lower postoperative pain, easier wound care, higher rate of symptoms resolution, and greater patient appreciation compared to MM, even though it had a higher recurrence rate. Larger comparative studies are needed to address this issue.
痔病(HD)是一种常见疾病,迄今为止已经提出了几种手术技术,但仍未能就其使用和适应证达成明确共识。激光痔切除术(LHP)是一种治疗 HD 的微创手术,通过二极管激光缩小痔核,从而限制术后不适和疼痛。本研究旨在评估 LHP 与传统的Milligan-Morgan 痔切除术(MM)治疗 HD 患者的术后结果。
回顾性评估 LHP 与 MM 治疗 III 级症状性 HD 患者的术后疼痛、伤口护理管理、症状缓解、患者生活质量和恢复日常活动的时间。对复发脱垂痔或症状的患者进行随访。
2018 年 1 月至 2019 年 12 月,93 例患者接受传统 Milligan Morgan 治疗作为对照组,81 例患者接受 1470nm 二极管激光治疗。两组均未发生明显的术中并发症。激光痔切除术患者的术后疼痛评分较低(p<0.0001),伤口管理更平稳。在 25±8 个月的随访中,Milligan-Morgan 组的症状复发率为 8.1%,激光痔切除术组为 21.6%(p<0.05),Rorvik 评分相似(LHP 组为 7.8±2.6,MM 组为 7.6±1.9,p=0.12)。
在选择的 HD 患者中,LHP 显示出较高的疗效,与 MM 相比,LHP 能保证较低的术后疼痛、更轻松的伤口护理、更高的症状缓解率和更好的患者满意度,尽管其复发率较高。需要进行更大规模的比较研究来解决这一问题。